Browse more cannabis research, findings, methods, and limitations.
Review found targeting cannabinoid receptors on peripheral nerves could provide pain relief without psychoactive effects, with promise for diabetic and chemotherapy neuropathy.
MS patients who smoked cannabis had more widespread cognitive deficits linked to brain volume loss in the thalamus, basal ganglia, and prefrontal regions compared to non-using MS patients.
Study identified sterilization methods for medical cannabis that eliminate dangerous mold contamination with minimal cannabinoid activity loss, protecting immunocompromised patients.
Ten CHS patients went nearly 20 months before diagnosis and were frequently misdiagnosed. All who resumed cannabis use relapsed, while abstainers remained symptom-free.
THCV, a cannabis-derived CB1 neutral antagonist, altered brain connectivity in ways relevant to obesity without subjective effects, suggesting potential as a safer alternative to rimonabant.
Among homeless people in BC, cannabis users had 32% psychotic disorder rates linked to childhood neglect, while stimulant users were more likely female and poly-substance users.
Review found cannabis constituents and FAAH inhibitors could complement MS treatment through dual symptom relief and anti-inflammatory/neuroprotective mechanisms.
Study of 49 women found endocannabinoid enzymes in the uterine lining change across the menstrual cycle, with degrading enzymes peaking during the implantation window.
Twin study of nearly 10,000 teens found the cannabis-psychotic experience association is driven by shared environmental factors (69-100%) rather than genetics, with cannabis explaining only 2-5% of psychotic experience variance.
All tested cannabinoids, including THC, CBD, and endocannabinoids, inhibited brain mitochondrial energy production through a mechanism independent of cannabinoid receptors.
Cochrane review of 23 trials found cannabinoids better than placebo for chemotherapy nausea (RR 5.7) and preferred by patients, but no comparison with modern anti-emetics exists.
MRI study found past cannabis use was linked to distinct hippocampal shape changes in healthy people (correlated with memory problems) vs. schizophrenia patients (correlated with use duration).
fMRI study found 14-year-old cannabis users had exaggerated amygdala reactivity to angry faces and impaired cortical threat regulation compared to matched non-users.
Review found marijuana lowers eye pressure for only 3-4 hours, requiring 6-8 daily doses that would cause significant side effects, making it impractical for glaucoma treatment.
Mouse study found inflammation suppresses an endocannabinoid-degrading enzyme in the spleen, potentially boosting anti-inflammatory endocannabinoid signaling as a natural feedback mechanism.
Both inverse agonist and neutral antagonist precipitated withdrawal in cannabis-dependent mice, showing withdrawal results from receptor competition, not inverse agonism, and is centrally mediated.
Alcohol and cannabinoid signaling showed opposing effects at inhibitory synapses in the rat amygdala, with each system blocking the other's actions.
Vaping cannabis reduces toxic smoke exposure, but the lung health advantage over smoking may be smaller than the benefit e-cigarettes offer over tobacco.
Analysis of 36,000+ marijuana-related tweets found mostly positive attitudes among adolescents, with personal use disclosures increasing after two states legalized recreational cannabis.
Brain imaging revealed that heavy cannabis users lacked the balanced dopamine receptor signaling between striatal regions that healthy controls displayed during a reaction-time task.
Belgium's switch from urine to oral fluid roadside drug testing cut the false positive rate from 17% to 8%, though cannabis confirmation rates also changed.
Blocking the enzyme that breaks down the endocannabinoid 2-AG delayed seizure development in a mouse epilepsy model, but had minimal effect once seizures were established.
Mice lacking the anandamide breakdown enzyme responded normally to THC but showed enhanced sensitivity to the THC-like effects of anandamide and 2-AG boosting drugs.
Adolescent THC exposure in rats produced over 1,000 regions of altered DNA methylation in their unexposed offspring's brain reward center, affecting glutamatergic signaling genes.
A new urine test for cannabinoids achieved 10-100x greater sensitivity than existing methods, capable of detecting secondhand marijuana smoke exposure.
A national survey found that people with IBD had higher rates of cannabis use (67.3% vs. 60%), started younger, and used more per session than matched controls.
79 RCTs: strong signal for chemo nausea, but pain relief averaged under 0.5 points on a 0-10 scale.
THC and a 2-AG boosting drug reduced brain reward self-stimulation in mice, while boosting anandamide alone had little effect, all mediated through CB1 receptors.
A nursing guide describes cannabinoid hyperemesis syndrome, characterized by severe vomiting in regular cannabis users that responds to hot bathing and cessation but not standard antiemetics.
A survey of 200 Rhode Island dispensary patients found most were male, college-educated, and insured, using cannabis primarily for chronic pain, with 20% reporting a substance use history.
Bipolar patients who quit cannabis during a manic episode had outcomes similar to never-users over two years, while those who continued using had lower recovery, higher recurrence, and more work impairment.
A review of animal research found that prenatal cannabinoid exposure can produce lasting immune dysfunction in offspring through epigenetic mechanisms like altered DNA methylation and microRNA.
A comparison of medical cannabis programs in Israel and Canada found both countries maintain strict regulations, specific approved conditions, and no insurance coverage for raw marijuana.
A clinical review found cannabis helps cancer patients with pain, nausea, appetite, and neuropathy, with preclinical data hinting at possible anti-tumor effects that lack clinical trial confirmation.
Blocking CB1 receptors reduced binge alcohol and sucrose consumption in adolescent mice to adult levels, suggesting the endocannabinoid system drives age-related differences in binge drinking.
A review found that cannabis may relieve IBD symptoms but lacks evidence of anti-inflammatory effects, with animal models showing promise that human trials have not yet confirmed.
The atypical cannabinoid O-1602, a GPR55 receptor agonist, reduced morphine reward and physical dependence symptoms in mice, suggesting a potential new target for opioid dependence.
A clinical review documented the rise of synthetic cannabinoids and other designer drugs, noting unpredictable toxicity, psychosis risk, and evasion of standard drug tests.
Among 100 hospitalized male bipolar patients, current substance use tripled violence risk, with cannabis, alcohol, and synthetic cannabinoids as the most common substances.
Cannabinoid treatment during late adolescence reversed cognitive deficits and reduced anxiety caused by early life stress in rats, with sex-specific differences in brain receptor changes.
A clinical review examined the evidence on adolescent cannabis use in the context of expanding legalization, covering risks, legal frameworks, and clinical considerations.
Cannabis and tobacco smoke both induce CYP1A2 (additively), THC and CBD are primarily metabolized by CYP3A4, and CBD may inhibit CYP2C19, all with implications for drug interactions.
A clinical review found cannabinoids offer modest benefits for nausea and inconsistent benefits for pain, while risks include cognitive impairment, driving accidents, dependence, and psychosis.
Estradiol suppressed reproductive hormone neurons through a pathway requiring both estrogen receptor beta and endocannabinoid 2-AG/CB1 signaling in mouse brain slices.
A survey of 225 Canadian MS patients found 19.5% currently use cannabis (mainly for sleep, pain, anxiety, spasticity), with half saying they would use if legal.
A policy review argued that the legal consequences of juvenile cannabis arrests (records, expulsions, loan ineligibility, racial disparities) often cause more harm than the drug itself.
Synthetic cannabinoid JWH-018 and two halogenated variants impaired memory in mice more potently than THC, disrupting hippocampal synaptic transmission through CB1 receptors.
In a nationally representative sample, alcohol was the most common first substance among US 12th graders, and earlier alcohol initiation predicted significantly greater illicit drug involvement.
A review found minimal evidence for prenatal cannabis exposure causing childhood aggression, and only a marginal, largely confounded association between adolescent use and aggressive behavior.
Among 210 people with gender dysphoria, 31.4% had social anxiety disorder, with current cannabis use nearly quadrupling the odds in multivariable analysis.